Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Upadacitinib (giant cell arteritis) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A25-66
Last updated

Report documents

  1. Extract of dossier assessment

    Upadacitinib (giant cell arteritis) Benefit assessment according to §35a SGB V

    published on
    Document type
    PDF document, 516 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-66_en
    Download file : Extract of dossier assessment (PDF document, 516 kB, EN, not accessible)

  2. Dossier assessment

    Upadacitinib (giant cell arteritis) Benefit assessment according to §35a SGB V

    published on
    Document type
    PDF document, 976 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-66
    Download file : Dossier assessment (PDF document, 976 kB, DE, not accessible)

Dossier assessment

Indication:

Adults with giant cell arteritis

Result of dossier assessment:
  • Patients who are candidates for therapy with glucocorticoids alone: added benefit not proven
  • Patients who are not candidates for therapy with glucocorticoids alone: added benefit not proven

Additional information

Federal Joint Committee (G-BA)

2025-11-06 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A25-66
Commission
Commission awarded on 15.05.2025 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A25-66_en

Connected Projects

  1. Dossier assessment

    Upadacitinib (Crohn disease) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-38
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Upadacitinib (axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-92
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Upadacitinib (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-91
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Upadacitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-116
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Upadacitinib (ankylosing spondylitis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-16
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Upadacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-15
    Last updated

    Status: Commission completed

  7. Dossier assessment

    Upadacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-08
    Last updated

    Status: Commission completed

  8. Addendum

    Upadacitinib (giant cell arteritis) – Addendum to Project A25-66

    Project no.
    A25-125
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page